United States

Back to map

Showing 271-280 of 334 grants

Title Institution Researcher Program Duration Total Award Amount
Phenotyping RElatives of persons with Diabetes with CGM and Tests of beta-cell function and health (PREDICT): an integrated longitudinal assessment of deep metabolic phenotyping and CGM metrics in youth at risk for T1D Yale University Alfonso Galderisi Cures 01-February-2023 to 31-January-2026 $747.380,88
PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) Rutgers, The State University of New Jersey Chintan Dave Cures 01-August-2022 to 31-July-2025 $695.404,04
Novel Combination Regimen Therapy to Modulate Pro- and Anti-inflammatory Lipid Signaling to Counter T1D The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham Sasanka Ramanadham Cures 01-July-2022 to 30-June-2025 $900.000,00
Combination of anti-CD3 mAb and antigen specific nanoparticles for prevention and treatment of Type 1 diabetes Yale University Kevan Herold Cures 01-June-2022 to 30-April-2025 $599.031,21
Targeting type 1 Diabetes through Polyamines with DFMO Trustees of Indiana University Emily Sims Cures 01-October-2022 to 30-September-2026 $3.693.701,00
Repurposing Cardiorenal Drugs for T1D: Building Evidence from Existing Trials (ReCaRD T1D) AdventHealth Richard Pratley Improving Lives 01-September-2023 to 31-August-2025 $110.840,00
Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes University of Washington Ian De Boer Improving Lives 01-September-2023 to 31-August-2026 $2.107.411,00
Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial Joslin Diabetes Center Inc. Alessandro Doria Improving Lives 01-January-2024 to 31-December-2028 $8.913.450,00
Reducing Glycemic Variability to Improve Cardiovascular Health in Type 1 Diabetes Rector & Visitors of the University of Virginia William Horton Improving Lives 01-December-2022 to 30-November-2025 $858.072,00
Preclinical evaluation of SERCA2 activators for pancreatic beta-cell protection in T1D Neurodon LLC Russell Dahl Cures 01-June-2022 to 31-May-2026 $920.000,00